Novo Nordisk Annual Sales Jump on Demand for Ozempic and Wegovy
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.
Read more at The New York Times
-
Novo Nordisk shares rise on fourth-quarter profit beat, Wegovy sales jump
Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring demand for its Wegovy obesity drugs.CNBC - 2h -
Novo Nordisk sales beat estimates, but the story wasn’t Ozempic
Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs.MarketWatch - 9h -
Novo Nordisk Foundation Will Not Fill Funding Gaps
Global health experts have questioned how philanthropies could mitigate Trump’s freeze on foreign health aid.Inc. - 1d -
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Expanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.CNBC - Jan. 28 -
Ozempic maker’s stock surges. A trial of a new Novo Nordisk drug shows promise.
Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much as 22%.MarketWatch - Jan. 24 -
Obesity drugs Ozempic and Wegovy included in US price-cut talks
Novo Nordisk shares hit as government adds blockbuster weight-loss treatments to new round of negotiationsFinancial Times - Jan. 17 -
Ozempic, Wegovy on list for Medicare drug price negotiations
The hugely popular medications Ozempic and Wegovy, used for diabetes and weight loss, will be included in the next round of talks to negotiate lower Medicare drug prices.CBS News - Jan. 17 -
Lululemon’s stock jumps as strong holiday sales show demand is improving
Lululemon’s stock rallies toward a 10-month high after guidance for profit, revenue and gross margin were raised.MarketWatch - Jan. 13 -
Ozempic maker Novo Nordisk, after trial disappointment, expands AI deal in potential $4.6 billion pact
At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish drugmaker reported disappointing results for its next-generation weight-loss ...MarketWatch - Jan. 8
More from The New York Times
-
As Big Retailers Pull Back on D.E.I, What Happens to Emerging Black Sellers?
Black-owned brands got a foot in the door through accelerator programs at companies like Target and Amazon. Now they worry it might be closing.The New York Times - 11h -
Trump Prepares to Take On the US Trade Deficit, a Familiar Nemesis
The trade deficit has long drawn the president’s ire. Now, he’s preparing to take it on again.The New York Times - 40m -
USPS Reverses Decision to Halt Parcel Service From China
The Postal Service will continue to accept parcels from Hong Kong and China despite a new executive order that will require greater inspection of packages.The New York Times - 5h -
Honda and Nissan Merger Talks in Peril
Two of Japan’s largest automakers have been in talks to combine their operations to form one of the world’s biggest car groups.The New York Times - 6h -
Trump Wants to Know Why U.S. Cars Are Rare in Germany. Here Are a Few Reasons.
German cars are popular in the United States, but U.S. cars are not as prevalent on German roads. One reason: tiny European streets and parking spots.The New York Times - 1d
More in Business
-
U.S. Trade Deficit Hit Record in 2024 as Imports Surged
A strong dollar helped drive an uptick in U.S. imports last year, while export growth remained modest.The New York Times - 8m -
Here's how Musk's access to Treasury system may impact Social Security, other government payments
The new Department of Government Efficiency now has access to a federal system responsible for $6 trillion in annual payments.CNBC - 12m -
New York Times Reports 350,000 Additional Digital Subscribers
Adjusted operating profit for the fourth quarter increased 10.7 percent from a year earlier, to $170.5 million, the company said.The New York Times - 18m -
Corporate profits are near all-time highs, while wages are near lows. How long can this last?
The U.S. has very high corporate profits, very high asset prices, very high fiscal deficits, very high trade deficits, and very low wages versus history, notes Deutsche Bank. Does something have to ...MarketWatch - 23m -
Big Tech stocks struggle after quarterly earnings as Alphabet sees steep drop
Alphabet has seen ‘one of the more negative reactions to earnings reports this earnings season,’ says Bespoke Investment GroupMarketWatch - 23m